Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Constitutional Genetics in Follicular Lymphoma (CONPIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03234140
Recruitment Status : Not yet recruiting
First Posted : July 31, 2017
Last Update Posted : July 31, 2017
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

Follicular lymphoma is the second most common adult B-cell lymphoma. The acquisition of the t(14;18) translocation is the genetic hallmark of Follicular lymphoma. However, 50% to 70% of healthy individuals harbor low levels of circulating t(14;18)-positive cells but will never develop Follicular lymphoma. It was observed that individuals who developed Follicular lymphoma showed a higher t(14;18) frequency than controls (Roulland et al., J Clin Oncol 2014). High t(14;18) frequency in blood from healthy individuals could be a predictive biomarker for Follicular lymphoma development. Genetic instability of those t(14;18)+ B-cells as well as failure of the micro-environment to control the proliferation of these cells are proposed mechanisms linking these lymphoma precursors to true lymphoma cells. The prognosis of Follicular lymphoma patients has been significantly improved mainly with the development of anti-CD20 monoclonal antibodies, with a current median overall survival over 15 years. However, this lymphoma remains an incurable disease. The most commonly used tool for prognostication of patients with Follicular lymphoma is the Follicular Lymphoma International Prognostic Index (FLIPI) based on conventional clinical and pathology parameters. Although it has clinical utility, the Follicular Lymphoma International Prognostic Index does not reflect the biologic heterogeneity of Follicular lymphoma. First-degree relatives of Follicular lymphoma had a fourfold increased risk of Follicular lymphoma suggesting a genetic etiology.

Using the Genome wide association studies (GWAS) approach on Follicular lymphoma cohorts of 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data. The investigators also plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in 318 healthy individuals included in EPIC cohort that will develop Follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk Follicular lymphoma individuals.


Condition or disease Intervention/treatment
Follicular Lymphoma Genetic Predisposition to Disease Genetic: Genome Wide Association Studies Genetic: Single-nucleotide polymorphisms's genotyping

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1883 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Constitutional Genetics to Predict Prognostic and Somatic Alterations in Follicular Lymphoma
Estimated Study Start Date : November 2017
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Group/Cohort Intervention/treatment
Group "Genome Wide Association Studies"

Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :

  • PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396
  • RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441
  • FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229
  • MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178
  • MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321

Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.

Genetic: Genome Wide Association Studies
Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.

Group "EPIC"

Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).

The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals.

Genetic: Single-nucleotide polymorphisms's genotyping
Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels




Primary Outcome Measures :
  1. Event Free Survival [ Time Frame: 1 year ]

    Event Free Survival for follicular lymphoma patients treated with modern immunochemotherapy in five cohorts is the primary end point defined as the time from the diagnosis or randomization to the date of progression, relapse, re-treatment, or death from any cause.

    Two steps analysis, with a discovery cohort and a validation cohort :

    The discovery cohorts that the investigators plan to study are a subset of patients with available deoxyribonucleic acid samples of two prospective phase III trials (PRIMA (NCT00140582) (N=396) and FOLL-05 (NCT00774826) (N=229), and one prospective observational cohort SPORE of the University of Iowa-Mayo Clinic (MER1; N=178). A GWAS will then be performed on a subset of patients with available deoxyribonucleic acid of two validation cohorts (Prospective observational SPORE MER2; N=321, phase III trial RELEVANCE, NCT01476787, N=441).



Secondary Outcome Measures :
  1. Somatic alterations and tumor biology [ Time Frame: 2 years ]

    In order to better decipher the impact of host genetics on somatic alterations and tumor biology and understand the physiological function of the single-nucleotide polymorphism identified from the primary outcome measure, we will study the link between the molecular profiles of the tumor and the prognostic single-nucleotide polymorphism. This will be performed on samples of the PRIMA and MER studies, for which we have access to somatic and constitutive data.

    In parallel, we will investigate the relation between known susceptibility single-nucleotide polymorphism and the level of the t(14 ;18) translocation. The latter analysis will be performed on EPIC samples (European Prospective Investigation Into Cancer and Nutrition), comparing healthy individuals to individuals who developed a follicular lymphoma. Finally, we will assess the effect of susceptibility single-nucleotide polymorphism on somatic molecular profiles on PRIMA and MAYO cohorts.



Biospecimen Retention:   Samples With DNA
Peripheral blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Group "Genome Wide Association Studies" :

Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :

  • PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396
  • RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441
  • FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229
  • MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178
  • MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321

Group "EPIC" :

Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).

Criteria

Group "Genome Wide Association Studies"

Inclusion Criteria:

  • Follicular lymphoma treated in first line therapy treated by immunochemotherapy (PRIMA, FOL05, MER1 and 2, control arm of RELEVANCE trial)
  • Follicular lymphoma treated in first line therapy by Rituximab and Lenalidomide as part of the investigational arm of RELEVANCE trial
  • Available constitutional DNA samples for GWAS analysis with an accurate consent form for such genetic study
  • Available biological and clinical characteristics at diagnosis with a follow-up of the patient for event free survival analysis
  • 18 years of age or older

Exclusion Criteria:

  • A non-follicular lymphoma histology according to WHO 2016 classification (grade 1, 2, 3a follicular lymphoma)
  • Relapsed follicular lymphoma
  • Patients without an accurate consent form for constitutional genetic study
  • Patients with no available biological or clinical data and follow-up for the outcome analysis

Group "EPIC"

Inclusion Criteria:

  • Included in the EPIC Cohort (European Prospective Investigation into Cancer and nutrition study between 1992 and 2000)
  • Available constitutional DNA samples with an accurate consent form for such genetic study
  • 18 years of age or older

Exclusion Criteria:

  • Patients without an accurate consent form for constitutional genetic study
  • Patients with no available biological or clinical data and follow-up for the outcome analysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03234140


Contacts
Layout table for location contacts
Contact: Hervé Ghesquières, Pr 04 78 86 43 01 ext +33 herve.ghesquieres@chu-lyon.fr

Locations
Layout table for location information
France
Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon Not yet recruiting
Pierre-Bénite, France, 69495
Contact: Hervé Ghesquières, Pr    04 78 86 43 01 ext +33    herve.ghesquieres@chu-lyon.fr   
Principal Investigator: Hervé Ghesquières, Pr         
Sponsors and Collaborators
Hospices Civils de Lyon

Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03234140     History of Changes
Other Study ID Numbers: 69HCL17_0212
First Posted: July 31, 2017    Key Record Dates
Last Update Posted: July 31, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Genetic Predisposition to Disease
Lymphoma
Lymphoma, Follicular
Disease Susceptibility
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Disease Attributes
Pathologic Processes